Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S. Saito T, et al. Among authors: makimoto a. Clin Cancer Res. 2002 Apr;8(4):1014-20. Clin Cancer Res. 2002. PMID: 11948108 Clinical Trial.
Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor.
Kanda Y, Tanosaki R, Nakai K, Saito T, Ohnishi M, Niiya H, Chizuka A, Yakushijin K, Urahama N, Ueda K, Iijima K, Ando T, Matsubara H, Kami M, Makimoto A, Kobayashi Y, Tobinai K, Mineishi S, Takaue Y. Kanda Y, et al. Among authors: makimoto a. Br J Haematol. 2002 Jul;118(1):128-31. doi: 10.1046/j.1365-2141.2002.03693.x. Br J Haematol. 2002. PMID: 12100136 Free article.
Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution.
Nakai K, Mineishi S, Kami M, Saito T, Hori A, Kojima R, Imataki O, Hamaki T, Yoshihara S, Ohnishi M, Kim SW, Ando T, Fumitoh A, Kanda Y, Makimoto A, Tanosaki R, Kanai S, Heike Y, Ohnishi T, Kawano Y, Wakasugi H, Takaue Y. Nakai K, et al. Among authors: makimoto a. Transplantation. 2003 Jun 27;75(12):2135-43. doi: 10.1097/01.TP.0000066453.32263.F7. Transplantation. 2003. PMID: 12829926
Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T, Kishi Y, Fujimoto H, Matsuoka N, Okajima E, Komiyama M, Tobisu K, Wakayama T, Uike N, Tajima K, Makimoto A, Mori S, Tanosaki R, Takaue Y, Kakizoe T. Nakagawa T, et al. Among authors: makimoto a. Exp Hematol. 2004 Jul;32(7):599-606. doi: 10.1016/j.exphem.2004.04.006. Exp Hematol. 2004. PMID: 15246155 Free article.
A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease.
Hori A, Kanda Y, Goyama S, Onishi Y, Komeno Y, Mitani K, Kishi Y, Ogawa S, Imataki O, Chiba S, Kojima R, Hamaki T, Sakiyama M, Kami M, Makimoto A, Tanosaki R, Takaue Y, Hirai H; Japan Hematology and Oncology Clinical Study Group. Hori A, et al. Among authors: makimoto a. Transplantation. 2005 Feb 15;79(3):372-4. doi: 10.1097/01.tp.0000151001.64189.1d. Transplantation. 2005. PMID: 15699774 Clinical Trial.
106 results